Skip to main content
Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
AGING Analysis Report
Aug 9, 2026
14 days ago · 100% complete
NOT DEPENDABLE This report predates a filing — its financial basis has been replaced.
Report generated: Aug 9, 2026 · Filing on record since: Aug 23, 2026 · 14 days after
Archived report · generated Aug 9, 2026 · 12:23 AM · models: linear-pipeline · cost: $0.142
Back to latest →
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for McKesson Corporation (MCK) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +34 (−100…+100 Quality+Value blend) · Quality 55 · Value 16 · Sentiment 5 (timing only, not weighted) · Composite fair value $968.97 vs $875.51 at analysis

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysisthe core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

McKesson Corporation

MCK NYSE
Healthcare · Medical Distribution
Irving, TX 75039, United States mckesson.com Updated Aug 9, 12:01am
Price
$869.58
Market Cap
$101.8B
Employees
41,600
Beta
0.31
Avg Volume
1,084,240
Last Dividend
$3.28
CEO
Mr. Brian S. Tyler Ph.D.

McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings. Its pharmaceutical distribution business supplies branded, generic, specialty, biosimilar, and over-the-counter products, while its medical-surgical operations provide clinical supplies, logistics, and equipment support. McKesson also offers technology-enabled services that help healthcare organizations manage prescriptions, practice operations, and patient care workflows. Through its broad distribution network and service platforms, McKesson plays a central role in connecting manufacturers, providers, and pharmacies across the U.S. and internationally.

Runs with full report Generated: Aug 9, 2026 12:16am
Price Overview
Price at report time
$869.58
as of Aug 9, 12:17am (14d ago)
Change · Aug 9
-1.80 (-0.21%)
Day Range
$864.32 – $889.69
52-Week Range
$637.00 – $999.00
50-Day MA
$799.61
200-Day MA
$837.64
Volume
1,562,200.00
Right now · live
Log in to get the live feed
Members see the real-time price and the move since this report (over 14d).
Share Structure
Outstanding 120,000,000.00
Float 116,406,150.00
Free Float 97.0%
High free float — 97.0% of shares trade freely, ~3% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Last updated: Aug 9, 2026 12:23am (14d ago)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Aug 7, 2026 5:35am (16d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
TD Twelve Data statement HEX SEC filing
Industry comparison last run: Aug 17, 2026 10:04am
P/E Ratio (Price per dollar of earnings)
HEX
Stock Price / EPS (Diluted)
22.66
Stock Price: $869.58
EPS (Diluted): 38.38
P/B Ratio (Price vs net asset value)
HEX
Stock Price / Book Value Per Share
Stock Price: $869.58
Total Equity: -$1.78B
Shares: 124,100,000
EV/EBITDA (Total value vs operating profit)
HEX
Enterprise Value / EBITDA
16.27
Market Cap: $101.81B
Total Debt: $6.53B
Cash: $3.98B
EBITDA: $6.50B
Enterprise Value (Takeover price (cap + debt - cash))
HEX
Market Cap + Total Debt - Cash
$105.8B
Market Cap: $101.81B
Total Debt: $6.53B
Cash: $3.98B
Gross Margin (Revenue left after direct costs)
HEX
Gross Profit / Revenue
3.6%
Gross Profit: $14.55B
Revenue: $403.43B
Operating Margin (Revenue left after all operations)
HEX
Operating Income / Revenue
1.5%
Operating Income: $6.21B
Revenue: $403.43B
Net Margin (Revenue left as actual profit)
HEX
Net Income / Revenue
1.2%
Net Income: $4.76B
Revenue: $403.43B
ROE (Profit from shareholder equity)
HEX
Net Income / Total Equity
Net Income: $4.76B
Total Equity: -$1.78B
ROIC (Profit from all invested capital)
HEX
NOPAT / Invested Capital
Operating Income: $6.21B
Tax Rate: 17.8%
Equity: -$1.78B
Total Debt: $6.53B
Cash: $3.98B
Current Ratio (Can it pay short-term bills)
HEX
Current Assets / Current Liabilities
0.85
Current Assets: $57.21B
Current Liabilities: $67.02B
Debt/Equity (Leverage — debt vs equity)
HEX
Total Debt / Total Equity
Short-Term Debt: $0.00
Long-Term Debt: $6.53B
Total Debt: $6.53B
Total Equity: -$1.78B
Rev/Share (Top-line per share)
HEX
Revenue / Shares Outstanding
$3,250.85
Revenue: $403.43B
Shares: 124,100,000
Book Value/Share (Net assets per share)
HEX
(Total Assets - Total Liabilities) / Shares
Total Equity: -$1.78B
Shares: 124,100,000
FCF/Share (Real cash generated per share)
HEX
(Operating Cash Flow + CapEx) / Shares
$46.08
Operating CF: $6.16B
CapEx: -$436.00M
Shares: 124,100,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TD
Last Annual Dividend / Stock Price
0.4%
Last Dividend: $3.28
Stock Price: $869.58
Payout Ratio (Earnings paid out as dividends)
HEX
Dividends Paid / Net Income
Dividends Paid: N/A
Net Income: $4.76B
Dividends paid not available in cash flow statement
Industry Benchmarks
Last run: Aug 17, 2026 10:04am
Compares MCK against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Income Statement (Annual)
Last updated: Aug 7, 2026 5:35am (16d ago)
Metric 2022 2023 2024 2025 2026
Revenue $264.0B $276.7B $309.0B $359.1B $403.4B
Cost of Revenue $250.8B $264.4B $296.1B $345.7B $388.9B
Gross Profit $13.1B $12.4B $12.8B $13.3B $14.6B
Operating Expenses $11.1B $8.0B $8.9B $8.9B $8.3B
Operating Income $2.0B $4.4B $3.9B $4.4B $6.2B
Net Income $1.1B $3.6B $3.0B $3.3B $4.8B
EBITDA $2.4B $4.7B $4.2B $4.7B $6.5B
EPS $7.32 $25.23 $22.54 $25.86 $38.55
EPS (Diluted) $7.23 $25.03 $22.39 $25.72 $38.38
Balance Sheet (Annual)
Last updated: Aug 6, 2026 7:33am (17d ago)
Metric 2022 2023 2024 2025 2026
Cash & Equivalents $3.5B $4.7B $4.6B $5.7B $4.0B
Total Current Assets $46.2B $44.3B $48.0B $55.4B $57.2B
Total Assets $63.3B $62.3B $67.4B $75.1B $82.3B
Current Liabilities $48.5B $48.0B $52.4B $61.6B $67.0B
Long-Term Debt $5.9B $5.6B $5.6B $5.7B $6.5B
Total Liabilities $65.1B $63.8B $69.0B $76.8B $84.1B
Total Equity -$1.8B -$1.5B -$1.6B -$1.7B -$1.8B
Retained Earnings $9.0B $12.3B $15.0B $17.9B $22.3B
Cash Flow (Annual)
Last updated: Aug 7, 2026 5:35am (16d ago)
Metric 2022 2023 2024 2025 2026
Operating Cash Flow $4.4B $5.2B $4.3B $6.1B $6.2B
Capital Expenditure -$388.0M -$390.0M -$431.0M -$537.0M -$436.0M
Free Cash Flow $4.0B $4.8B $3.9B $5.5B $5.7B
Acquisitions (net) -$6.0M -$867.0M -$272.0M -$24.0M -$3.4B
Net Debt Issued / (Repaid) -$1.2B -$277.0M $703.0M -$21.0M $783.0M
Dividends Paid
Stock Buybacks -$3.5B -$3.6B -$3.0B -$3.1B -$4.8B
Net Change in Cash -$2.5B $744.0M -$94.0M $1.4B -$1.9B
Growth Trends (YoY %)
Last updated: Aug 7, 2026 5:35am (16d ago)
Metric 2023 2024 2025 2026
Revenue Growth +4.8% +11.7% +16.2% +12.4%
Gross Profit Growth -5.9% +3.8% +3.9% +9.2%
Operating Income Growth +115.0% -10.8% +13.1% +40.5%
Net Income Growth +219.6% -15.7% +9.8% +44.5%
EBITDA Growth +98.0% -10.0% +12.1% +38.5%
Dividend History (Last 20)
Last updated: Aug 6, 2026 7:33am (17d ago)
Date Dividend Declaration Record Payment
2026-06-01 $0.82
2026-03-02 $0.82
2025-12-01 $0.82
2025-09-02 $0.82
2025-06-02 $0.71
2025-03-03 $0.71
2024-12-02 $0.71
2024-08-30 $0.71
2024-06-03 $0.62
2024-02-29 $0.62
2023-11-30 $0.62
2023-08-31 $0.62
2023-05-31 $0.54
2023-02-28 $0.54
2022-11-30 $0.54
2022-08-31 $0.54
2022-05-31 $0.47
2022-02-28 $0.47
2021-11-30 $0.47
2021-08-31 $0.47
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable 18 computed · 6 not applicable
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-23 02:55
19.0 : 1 recovery upside vs repeat-quarter downside
Recovery pays +609%; another quarter like the worst recent one costs 32%. Ratio 19.0:1.
CaseGrowthMarginFair valuevs price ($875.51)
Bull — recovery +19% 9.2% $6,205.00 +609%
Base — stabilizes +12% 8.0% $4,435.92 +407%
Bear — keeps slipping +6% 6.8% $3,077.55 +252%
Stress — last quarter repeats +6% 1.2% $594.97 -32%
The next quarters keep the trajectory of the worst recent matched quarter (ending 2026-03-31) — growth stays at 6.0% and margins bend by the same profit-vs-revenue ratio (×1.10). Stress is a trajectory, not a prediction — it answers "what if the ship's current heading simply continues," which history says is the case to respect.
Why this is appearing: this company files quarterly, so its recent trajectory could be measured rather than assumed — the engine matched Jun 2026 against the same quarter one year earlier and found revenue +7.7% · operating income +27.3% · net income -21.7% year-over-year. That measured heading is what the stress case extends forward. Of those, the stress case extends the worst matched quarter — the one ending Mar 31, 2026 (revenue +6.0%, operating income +35.1% YoY) — not the average. Data measured through Jun 30, 2026 — this card recalculates automatically when the next quarterly filing is ingested. Companies without quarterly filings (many foreign listings) never show this card: with no measured trajectory, there is nothing honest to repeat.
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MCK — it's generated by the pipeline (market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-17
The creme is there an opportunity here? Conditional opportunity
AI is a cost tailwind on a 1.5%-margin, $403B throughput machine and a threat only to the software wing the bulls are paying up for — so the trade is long the physical moat, skeptical of the mix-shift story.
Position 60 with exposure 40: the licensed distribution core is close to AI-proof (entrant_compression 73, responsibility_transfer 79), and operating leverage on razor-thin margins means modest automation gains land directly in EPS. The soft spot is Prescription Technology Solutions, whose per-transaction access fees are the most AI-replicable revenue McKesson owns — if PTS growth converges toward distribution growth, the premium mix-shift narrative deflates even as earnings hold. Watch PTS segment revenue and operating profit decomposition, Ontada data-contract disclosure, and any manufacturer moving hub/access services in-house; those three read out before the market reprices.
60
AI Position
Moderately favorable — physical core insulated, software wing is the real exposure
Cheap intelligence barely touches McKesson's licensed physical drug-distribution core but decides the fate of its highest-margin information businesses (CoverMyMeds/Prescription Technology Solutions, Ontada oncology data), making the net effect mildly positive with a narrow but real soft spot.
Exposure 40 Confidence 67 50 = neutral
Primary Tailwind

On a 1.5% operating margin, AI-driven cost takeout in warehouse operations, order-to-cash, generics sourcing analytics, and back-office/customer service converts into outsized EPS leverage — a 10bp SG&A improvement on $403B of revenue is material to a company earning $4.8B.

Primary Pressure

Prescription Technology Solutions monetizes friction: prior authorization, benefit verification, and copay/affordability workflows. If AI (plus interoperability mandates) makes electronic PA near-costless for payers, EHRs, and pharma hubs to run in-house, the per-transaction fee pool that drives McKesson's margin mix-shift compresses.

Critical Hinge

Whether PTS revenue and segment operating profit keep compounding faster than distribution once AI-native access/hub tooling is widely available — watch PTS segment growth and margin decomposition (technology services vs. third-party logistics pass-through) quarter by quarter.

Hard to Reproduce

DEA/state licensure, controlled-substance suspicious-order monitoring built under settlement oversight, DSCSA-serialized cold-chain and specialty logistics, manufacturer contract economics at three-way oligopoly scale, and the US Oncology Network's longitudinal oncology EHR dataset.

Forensic fingerprint same 11 factors for every stock · 0 unfavorable · 50 neutral · 100 favorable
Underlying Need Persistence do people still need this at all? 93
Drugs must be physically sourced, stored, and delivered to ~pharmacies, clinics, and health systems regardless of intelligence costs.
The need is molecule movement under regulatory chain-of-custody, not information processing; cheap AI does not reduce the number of prescriptions dispensed or doses infused.
US script and specialty volume trends · GLP-1 and specialty unit growth · Site-of-care shifts away from distribution
relevance 72 · confidence 88
Solution Persistence will they still solve it this way? 78
Wholesale three-tier distribution survives AI, but the software/access layer's delivery form is less certain.
No AI substitute exists for licensed, serialized, temperature-controlled national logistics; the vulnerable part is prior-auth/copay workflow software, where the mechanism of solving the need can change.
Manufacturer direct-to-patient program expansion · Payer-side automated PA adoption · Contract renewals with top pharmacy customers
relevance 76 · confidence 74
Intelligence Commoditization does cheap AI power them or copy them? 56
Cheap AI powers McKesson's operations more than it copies them, except in the access-software wing.
Commodity intelligence improves demand forecasting, warehouse labor productivity, and generics sourcing; the same abundance lets EHR vendors and payers replicate CoverMyMeds-style automation cheaply.
EHR-native prior auth automation launches · AI-native pharma hub service startups · McKesson opex per revenue dollar
relevance 58 · confidence 63
Responsibility Transfer are they paid to take the blame? 79
Customers and manufacturers pay McKesson partly to carry DEA, DSCSA, and product-integrity accountability.
Post-opioid-settlement suspicious-order monitoring, licensure, recall management, and serialization liability sit with the distributor; a hospital or pharmacy chain cannot cheaply assume that exposure with internal software.
New controlled-substance compliance obligations · Recall and integrity incident frequency · Customer self-distribution announcements
relevance 70 · confidence 76
Scarcity Migration do their assets get rarer or more common? 63
As software becomes abundant, licensed physical networks and proprietary oncology data become the relatively scarce assets.
Distribution centers, cold chain, DEA registrations, and manufacturer contract terms cannot be spun up by capital plus code; oncology longitudinal data gains value as AI models need clinical ground truth.
Ontada data and AI contract wins · Specialty/oncology capacity investments · New entrant distribution licensing attempts
relevance 66 · confidence 66
Customer DIY Preference will customers just build it themselves? 67
Nobody wants to own drug logistics; some customers may want to own access workflows.
Health systems and independent pharmacies avoid internalizing inventory risk and controlled-substance compliance, but payers and large manufacturers have both incentive and AI tooling to internalize benefit-verification workflows.
Health system self-distribution pilots · Pharma insourcing of hub services · Large IDN contract structure changes
relevance 56 · confidence 66
AI Intermediation Position do AI agents go through them or around them? 57
Agents ordering drugs still route through licensed distributors, but AI-fronted direct channels can bypass wholesale for select brands.
Automated replenishment at pharmacies flows into McKesson's rails and may increase order frequency; conversely manufacturer digital front doors paired with mail pharmacies can disintermediate the profitable branded slice.
Share of branded volume via direct channels · Automated replenishment integration wins · Amazon/mail pharmacy sourcing arrangements
relevance 62 · confidence 60
Data Leverage does their data make AI better? 66
Oncology EHR and dispensing data are genuinely AI-relevant inputs, monetizable to manufacturers.
US Oncology Network clinical data plus national dispensing visibility feed real-world evidence, trial matching, and commercial analytics that AI makes more valuable per record than manual abstraction did.
Ontada revenue disclosure and growth · Pharma RWD contract durability · Competing RWD sources from payers/EHRs
relevance 60 · confidence 60
AI Margin Conversion do the AI savings become profit? 54
Thin-margin, tender-driven contracts mean part of any AI cost gain is competed back to large customers.
Gross margin has drifted from 5.0% to 3.6% as revenue mix shifted to high-cost specialty; the three-way oligopoly retains some pricing discipline, so AI savings should partly stick in operating margin (already up to 1.5%) rather than fully passing through.
Operating margin trend excluding mix · SG&A as percent of gross profit · Distribution center automation capex
relevance 68 · confidence 62
Revenue Unit Durability does the thing they charge for survive? 72
The monetized units — drug volume and fee-for-service on manufacturer contracts — survive AI; per-transaction software fees are shakier.
Distribution earns on throughput and generics sourcing spread, which cheap intelligence does not shrink; PTS earns per prior-auth or affordability transaction, a unit that automation and regulation can devalue.
PTS revenue vs technology-fee mix · Prior-auth transaction pricing trends · Generics sourcing profit contribution
relevance 72 · confidence 68
Entrant Compression how easily can newcomers copy them? 73
AI lowers the cost of building software competitors, not licensed national drug distribution.
An AI-native entrant cannot replicate DEA licensure, DSCSA compliance, cold-chain capacity, and manufacturer contract scale; it can plausibly replicate an access-workflow platform, which is exactly where McKesson's mix-shift growth lives.
Funding of AI pharmacy-access startups · Manufacturer RFPs for hub services · New specialty distributor entrants
relevance 62 · confidence 70

AI Lens thesis

McKesson's economics rest on physical throughput of licensed, high-value molecules and on being the entity regulators and manufacturers hold accountable for chain-of-custody — neither of which cheapens when intelligence does; AI arrives instead through three narrow channels: it compresses the cost of running a $403B logistics and receivables machine (accretive on razor-thin margins), it raises the market value of proprietary oncology real-world data and trial-matching capability (Ontada), and it threatens the per-transaction fee logic of the access/affordability software layer that the bull case depends on for mix-shift; the distribution moat is not code, so AI-native entrants cannot compress it, but AI-enabled direct-to-patient manufacturer channels can route around parts of it for specific branded drugs.

Thesis breaker PTS revenue growth decelerating toward distribution growth with flat-to-down segment margin, or a major manufacturer moving hub/access services in-house on AI tooling, would invalidate the favorable read; conversely a step-up in Ontada/pharma data-and-AI contract revenue would push it higher.
What the market may be underestimating

Upside AI makes proprietary oncology real-world data and automated trial matching far more valuable to pharma than legacy chart-abstraction economics implied; Ontada plus the US Oncology practice footprint is a data asset the market prices as a services line, not an AI-scarce input.

Downside AI-fronted direct-to-patient manufacturer channels for high-priced brands (self-pay digital pharmacies bypassing the three-tier chain) can quietly erode the most profitable branded volume, while distributor productivity gains get competed back to large pharmacy customers at contract renewal.

Outcome range spread 33

42Bear case
60Central case
75Bull case
Three headline numbers, deliberately never blended: Position (which way), Exposure (how much it matters at all), Confidence (how sure). The fingerprint asks every stock the same 11 questions so companies a sector label would lump together get told apart. Not an input to GEM/Coal or the Q/V/S lenses.
Growth Outlook
Analyzed 2026-08-17 16:18

The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.

Growing Volume-rich pharmaceutical distribution plus specialty/oncology and prescription-technology mix shift keeps mid-to-high single digit revenue growth converting into low-to-mid teens EPS growth, with buyback leverage on top — durable Growing, not Accelerating, since the revenue line is already decelerating off GLP-1 comps. conf 7/10
Inline with category Category growing · Category median recent growth is ~12.4%, essentially identical to MCK's ~12.4% revenue YoY — MCK is growing with a growing category, not ahead of it, on the top line. Where it diverges is profit conversion: earnings growth (+44.5% YoY, 26% multi-year CAGR) runs well ahead of the industry's 18% earnings CAGR, indicating mix and services share gains inside the same volume pool rather than raw share capture.
Next 2 quarters
Growing
Volume backlog is visible: specialty/oncology contracts already signed, prescription-technology attach growing, buyback running. The five most recent prints all exceeded EPS estimates (+1% to +12%), and management's pattern is guide-conservatively-then-raise. Top-line growth rate likely eases as comps harden, but earnings dollars keep climbing.
↑ above expectations
Year 1
Growing
Full-year shape: mid-to-high single digit revenue growth after GLP-1 comps normalize, high-single to low-double-digit operating income growth from oncology/multispecialty and Rx tech, plus share count shrink. Med-Surg remains the swing factor and could shave a point of segment growth, but it is too small to change the company call.
≈ inline with expectations
Years 2–3
Growing
Structural earnings power grows: specialty volume density and community-oncology consolidation are multi-year, services revenue is recurring, and the EPS algorithm compounds via buybacks funded by strong FCF even as opioid payments run. Risks (customer renewals, generic deflation, disintermediation) trim the rate rather than reverse the direction; nothing in evidence supports Accelerating.
↑ above expectations
The creme: each rung's call measured against what's already printed (vs analyst estimates · vs guidance / FY consensus · vs price-implied growth) — expectations in print are already in the price, so only the variant margin can pay. Hover a rung's chip for the margin read.
Growth drivers
71 Specialty & oncology mix shift — Oncology and Multispecialty (US Oncology Network, community-practice roll-ups, vision/retina platforms) grows faster than commodity distribution and carries higher fee-for-service and services economics. This is the mechanism behind operating income growing far faster than revenue (recent earnings YoY +44.5% vs revenue +12.4%) and it is contractual/embedded, not a one-quarter effect.
58 Volume-led distribution economics on branded/GLP-1 scripts — Distribution is paid on units and fee-for-service, not on drug price, so record GLP-1 and specialty script volume flows through with minimal incremental cost. Low gross margin percentage but high absolute contribution; three-player oligopoly (MCK/COR/CAH) means no need to buy volume with price.
39 Prescription Technology Solutions — Access/affordability and adherence software attached to manufacturer hub programs is recurring, higher-margin, and grows with the same specialty launch cycle that drives distribution volume — a second, structurally different growth engine rather than a story about 'software'.
53 EPS algorithm: leverage + share shrink — Consistent, sizeable repurchase converts ~high-single-digit operating income growth into low-to-mid-teens EPS growth. Mechanical, self-funded by strong FCF (FCF CAGR 21%), and independent of end-market surprises.
46 Category in expansion phase — Sector demand cycle in expansion, industry revenue CAGR 8.3% and earnings CAGR 18.1%; aging demographics, biologic/biosimilar launch density and site-of-care shifts give the pipe more volume each year regardless of MCK's own execution.
Growth risks
50 Revenue deceleration as volume comps lap — Revenue confidence data flags the quarterly trend as decelerating. Much of the 12%+ top line is pass-through mix (GLP-1, branded inflation) that laps hard; the reported growth rate almost certainly steps down even if profit dollars keep compounding.
42 Customer concentration and contract renewals — A small number of very large retail/PBM-affiliated customers represent an outsized share of volume. Any renewal at worse economics, insourcing, or a retail-pharmacy bankruptcy removes revenue instantly and is outside management's control.
22 Medical-Surgical Solutions softness — The primary-care/post-acute supply segment is exposed to illness-season variability and utilization softness, and has repeatedly been the drag inside otherwise strong prints. Small share of revenue but a visible earnings-mix headwind.
20 Opioid settlement cash drain and residual legal tail — Multi-year fixed settlement payments consume free cash flow that would otherwise fund buybacks/M&A; incremental claimants remain possible. Known and scheduled, so it caps rather than reverses growth.
21 Generic deflation and vertical integration/disintermediation — Persistent generic price erosion pressures the highest-margin part of the mix, and payer/provider vertical integration plus direct-to-patient manufacturer channels chip at the pipe's role at the margin. Slow-moving and historically absorbed, not yet visible in results.
The world is pushing more drug value through fewer, larger pipes: biologics and specialty launches, GLP-1 mass adoption, aging demographics, and care migrating from hospital to community and home. Each of those adds units and complexity, and complexity is what a distributor is paid for. The offsetting force — payers, retailers and manufacturers trying to shorten the chain — is real but slow, and the capital intensity plus cold-chain/compliance scale of national distribution has repelled every entrant so far. Macro backdrop (4.63% 10y, headwind label) matters little: healthcare volume is non-discretionary and MCK's model is fee-based rather than price-levered, though higher rates do raise the bar on debt-funded roll-up M&A. Net: the environment supports steady volume growth with margin coming from services and specialty, not from distribution spread.
Growth position composite +44
ShrinkingStallingHoldingGrowingAccelerating
70Next 2 quarters · Growing
70Year 1 · Growing
70Years 2–3 · Growing
+44Composite (−100…+100)
A research prediction, not advice. Forward-graded: each rung is scored against the prints that follow it. Not an input to the GEM designation — track record first.
Claude Reading
Independent analyst synthesis · claude-opus-4-7 · generated 2026-08-17 10:14:32
Verdict I dissent from the synthesis. The composite fair value of $1,108 requires believing MCK deserves a growth multiple on cyclically-elevated earnings — I don't. A defensible fair value using 16-18x normalized EPS (~$38-40 run-rate ex-GLP-1 surge) lands closer to $650-720, meaning current $869 is 20-30% *overvalued*, not undervalued. That said, I'm only conviction-3 on this because: (1) FCF quality is genuinely strong and buybacks provide a floor, (2) the oligopoly structure (MCK/COR/CAH) is durable, and (3) if GLP-1 volumes stay elevated for another 2-3 years the "cyclical" earnings become the new base. This is a "wait for the multiple to normalize or growth to prove durable" name, not a starter-position name at $869. The models are reading a strong tape and confusing it with strong intrinsic value.

Starting from the raw numbers: MCK is a $400B+ revenue distributor running 3.6% gross and 1.5% operating margins, growing top line 14% CAGR and earnings 26% CAGR into FY26. That earnings growth on a wafer-thin margin business is real but mechanically fragile — a 20bp gross margin swing is roughly $800M pretax on $400B of revenue, which is bigger than a full quarter of net income. The FY26 print (rev $403B, NI $4.76B, OCF $6.16B, FCF $5.72B) is genuinely strong, and the June 2026 quarter at $105B rev with $614M NI shows the margin oscillation that defines this model — Q1 is seasonally the softest, so I wouldn't read the 0.6% margin as deterioration. FCF conversion (~120% of NI) is the tell that this is a real cash machine, not accounting earnings. Negative $1.78B equity is a buyback artifact, not distress — with $6.16B OCF against $6.53B debt, leverage is trivial.

Where I part ways with the synthesis: the "undervalued by 26.8%" composite ($1,108 signal-adjusted vs $869) is almost certainly overfitting the recent earnings acceleration. Distribution wholesalers have traded at 10-18x P/E historically for a reason — the business converts massive revenue into thin, contestable spread income. MCK at 22.8x trailing is already at the top of its historical band, and applying growth-stock multiples to a 1.2% net margin business is how you generate spurious upside. The 26% earnings CAGR is partly cyclical (GLP-1 volume surge, specialty pharma mix shift that's now well-known) and partly buyback-driven EPS math. Strip GLP-1 tailwind and you're likely back to 6-8% organic revenue growth and mid-single-digit EPS growth ex-buyback. The pre-flight note flagging "volume growth, not margin expansion" is the correct frame; the synthesis appears to ignore it.

The contrarian case that no model quite articulates: MCK's stock has roughly doubled in two years while operating margin moved from 1.4% to 1.5%. That's a re-rating, not a fundamental transformation. Insider activity confirms this — 8 sales vs 2 awards in the last 10 transactions, with sales dwarfing awards in share count (~25k sold vs ~8.4k awarded). "Neutral insider activity" undersells this; when insiders are net sellers at all-time highs in a mature distributor, that's a soft signal to trim, not add. The macro headwinds flag matters too: if drug pricing reform (IRA Medicare negotiation expansion, most-favored-nation pricing revival) compresses branded drug economics, distributor buy-side spreads get squeezed with no offsetting lever. The narrative layer's "21% discount to DCF" claim is doing a lot of work — DCFs on 1.5% operating margin businesses are wildly sensitive to terminal margin assumptions, and I'd want to see the sensitivity table before trusting any point estimate.

GPT Reading
Independent reading · gpt-5.4 · generated 2026-08-17 10:14:48
Verdict Fairly valued to slightly overvalued at $869 — a great distributor with elite cash generation, but the premium multiple already assumes margin resilience that recent quarterly data have not fully confirmed.

McKesson is a superb business in a structurally unattractive-looking format: more than $400B of annual revenue, but only 1.2% net margin and 1.5% operating margin. The key question is whether that should trade like a dull distributor or a high-quality compounder. The raw data push me toward the latter operationally but not fully at this price. Revenue has climbed from $263.97B in FY2022 to $403.43B in FY2026, a 53% jump in four years, while operating income expanded from $2.04B to $6.21B and net income from $1.11B to $4.76B. That is not just inflation or pass-through volume; operating leverage and mix clearly improved. Free cash flow of $5.72B on only $436M of capex shows the model’s real strength: this is an asset-light toll collector on drug distribution with unusually strong cash conversion for a company whose accounting margins look razor-thin.

What stands out, though, is that the quarterly pattern is less pristine than the annual trend implies. The latest quarter, June 2026, posted revenue of $105.38B, up from $97.83B a year earlier, yet net income was only $614M versus $784M, with margin falling to 0.6% from 0.8%. That follows a very strong March 2026 quarter at $1.68B of net income on $96.30B of revenue, so profitability is not steadily improving; it is lumpy and sensitive to mix, timing, and likely charges. Across the last eight quarters, net margin has ranged from 0.3% to 1.7%, which is a reminder that this is still a spread business where tiny changes matter enormously. At $101.3B market cap and about 21-23x trailing earnings, the market is valuing McKesson not as a commodity distributor, but as a high-confidence allocator of capital with durable earnings expansion. I can understand that, but I do not think the current quote leaves enough room for a business with this much margin fragility and a current ratio below 0.86.

The balance sheet is also more awkward than the equity story suggests. Net debt is manageable at roughly $2.6B after subtracting $3.98B cash from $6.53B debt, so solvency is not the issue. The issue is that total equity is negative $1.78B, which is usually the byproduct of aggressive buybacks and settlement accounting rather than economic distress, but it still reduces balance-sheet flexibility and makes the business look more robust on return metrics than it really is. EV/EBITDA around 17x is not cheap for a wholesaler, even a very good one. The low P/S of 0.27x is a red herring because gross margin is only 3.6%; revenue scale here is not equivalent to value creation. On trailing numbers, the stock is priced for continued double-digit EPS/FCF compounding, and that feels rich when recent quarterly profitability has already shown slippage.

The best argument against my caution is straightforward: McKesson has earned a premium because it keeps proving the skeptics wrong. Annual revenue growth from $308.95B to $403.43B in just two years is exceptional for a “mature” company, and operating income rose from $3.91B to $6.21B over that span, far faster than sales. Free cash flow of $5.72B against a $101B market cap is not optically cheap, but for a defensive healthcare infrastructure asset with limited capex needs and strong buyback capacity, it is not unreasonable either. If the March 2026 earnings power is more representative than the June quarter, then normalized net income may be running comfortably above the $4.76B annual base, making the P/E less demanding than it appears. A smart bull would also say negative equity is cosmetic here, not fundamental, and that the market is paying for oligopoly position, specialty mix improvement, and exceptional capital returns rather than for accounting book value.

What would change my mind is evidence that the June-quarter margin dip was noise rather than signal. If the next two quarters sustain revenue above $105B while restoring net margin to at least 1.1%-1.3%, that would imply annualized earnings power well above $5B and make the current valuation more defensible, even attractive. Conversely, if revenue keeps growing near 10% but net income stalls around $0.6B-$1.1B per quarter outside seasonal spikes, then the stock is too expensive for a low-margin distributor. I would also want to see free cash flow remain above $5.5B and no deterioration in working-capital discipline; with a current ratio under 1, this model works beautifully until it doesn’t.

Grok Reading
Independent reading · grok-4.5 · generated 2026-08-17 10:15:35
Verdict Fairly valued near $869; high-quality FCF compounder already priced at 23x with thin margin of safety after the soft June quarter

McKesson’s numbers describe a distribution oligopoly that has quietly become a compounding machine on volume and mix rather than price. Revenue climbed from $264B in fiscal 2022 to $403B in fiscal 2026, a 14.3% CAGR, while net income more than quadrupled from $1.11B to $4.76B and free cash flow reached $5.72B on only $436M of capex. Operating income expanded from $2.04B to $6.21B over the same span, lifting operating margin from roughly 0.8% to 1.54%—evidence that specialty pharma, oncology, and technology attachments are doing real work inside a 3.6% gross-margin business. At $869 and a $101B enterprise, the stock trades at 22.8x trailing earnings and a 5.6% FCF yield; those are not distressed multiples, but they are supported by mid-20s earnings and FCF CAGRs and by a balance sheet that, despite negative book equity of $1.78B, carries only $6.5B of debt against nearly $4B of cash and generates more than enough cash to fund buybacks and a token 0.4% dividend.

What stands out against the clean multi-year trajectory is the most recent quarter and the structural balance-sheet optics. June 2026 delivered $105.4B of revenue but only $614M of net income—a 0.6% margin that is less than half the prior quarter’s 1.7% and well below the trailing annual 1.2%. That volatility, combined with a current ratio of 0.85 and negative equity (the residue of aggressive repurchases plus opioid-related charges), is the quantitative counterweight to the “steady compounder” label. Insider activity over the last several months has been almost entirely sales, and the secondary signals flag decelerating quarterly revenue and macro headwinds. The valuation engine’s $939–$1,108 fair-value band therefore embeds an assumption that margin expansion and mid-teens growth persist; the raw quarterly print and the sub-1.0 current ratio say that assumption is not yet risk-free.

I place more weight on the cash-conversion engine and the oligopoly volume franchise than on the historical 10–18x wholesaler P/E band cited in the pre-flight note. A business that turns $400B of revenue into $5.7B of unlevered free cash with negligible reinvestment deserves a premium to pure commodity distribution, and the 26% earnings CAGR is not an accounting artifact. Still, at 23x and 17x EV/EBITDA the market has already paid for a large fraction of the specialty-mix and GLP-1 volume story. The 27% upside in the signal-adjusted composite looks optimistic once the latest quarter’s margin compression and the litigation tail are treated as recurring rather than one-off noise.

The strongest case against this read is straightforward: earnings power is still rising, FCF quality is graded strong, and a 5.6% free-cash-flow yield with double-digit growth is cheap relative to the broader healthcare complex if operating margins can stabilize near 1.5–1.8%. A bull would also note that negative equity is largely cosmetic—an artifact of buybacks in a low-tangible-asset model—and that the opioid overhang is increasingly quantifiable. I discount that optimism because the June quarter already showed how quickly a 1.7% margin can halve, revenue growth is flagged as decelerating, and 23x leaves little room for multiple compression if GLP-1 volumes or specialty attach rates disappoint.

I would flip to a clear undervalued stance if the next two quarters restore net margins above 1.2% on continued double-digit revenue growth and if fiscal 2027 guidance implies FCF above $6.5B; I would flip decisively overvalued if margins stay sub-1% or if another material opioid or channel charge appears that impairs the buyback capacity that has underpinned the equity story.

Big-3 Panel — where each AI stands
Each AI above independently stated a direction (undervalued, fairly valued, or overvalued) and how strongly it believes it (conviction, 0–5). We combine those into a Bull-Bear Index on a 0–10 scale: 5 is neutral, 10 is maximum bullish (undervalued at full conviction), 0 is maximum bearish. We compute the score ourselves with the same arithmetic for every seat — the models never grade their own bullishness — so the three are directly comparable. Δ shows how far each seat sits from the panel average of 4.0; a large Δ marks the dissenting voice, usually the one worth reading.
Claude claude-opus-4-7 2.0
overvalued · conviction 3/5 · Δ -2.0 vs panel · self: 3.0
GPT gpt-5.4 5.0
fairly valued · conviction 3/5 · Δ +1.0 vs panel · self: 4.0
Grok grok-4.5 5.0
fairly valued · conviction 3/5 · Δ +1.0 vs panel · self: 5.0
Advanced Analysis Forensic deep-dive · separate lenses
Separate reads — Company Quality (is it a great business?), Valuation (is it mispriced?), and General Sentiment (how macro + narrative are pushing it), plus AI Impact (how the AI wave reshapes it), kept deliberately apart · 2026-08-17 10:39:38
Delvantic - Cairn AI
Quality hold — starter only, add on a dip to $820 6/10
A high-quality, thin-margin distribution compounder trading roughly 7% below defensible fair value — a fine hold, not yet a fat pitch.
The cruxWhether the specialty/oncology mix-shift and buyback cadence sustain the recent earnings step-up, or the 1.5% operating margin drifts back down and collapses the DCF premium to the EPV floor.
Forensic checks Derived mechanically from MCK's filed financials — not from the AI lenses
Liquidity & RunwaySelf-Funding
DilutionShare Count Shrinking
Earnings QualityHigh Earnings Quality
The four lensesswitch a tab for its full read — score + evidence
Company Quality
+55
Strong
edge √Σ 136 · risk √Σ 75 · conf 8/10

McKesson is a mature earner operating in a structurally thin-margin industry (gross margin 3.6-5%, operating margin 0.8-1.6%), yet the trajectory is genuinely constructive: revenue has compounded from $264B in 2022 to $403B in 2026 (about 11% CAGR), net income has more than quadrupled from $1.11B to $4.76B, and FCF has grown from $4.05B to $5.72B. Operating margin recovered to 1.5% in 2026 after a 2024 dip, showing operating leverage is real, not just a mix artifact. Earnings quality checks are clean: OCF/NI at 2x, accruals -3% of assets, Beneish M at -2.36, and Altman Z of 6.11 all point to reported numbers being backed by cash.

Strengths 4
m78
Aggressive per-share concentration
Diluted share count fell from 154.1M (2022) to 124.1M (2026), a -5.3% CAGR — roughly 19% of the float retired in four years, meaningfully amplifying per-share economics.
m72
Clean earnings integrity
OCF/NI ~2x, negative accruals (-3% of assets), Beneish M -2.36, Altman Z 6.11 in safe zone — no mechanical red flags; the $5.72B FCF exceeds $4.76B net income, confirming cash-backed earnings.
m65
Consistent FCF generation at scale
FCF has ranged $3.88B-$5.72B across five years despite a low-margin model; self-funding with no reliance on external capital.
m55
Operating leverage emerging
Revenue grew 53% (2022 to 2026) while net income rose 4.3x — thin-margin distribution model showing scale benefits, with OpM recovering to 1.5% from a 2024 trough of 1.3%.
Concerns 4
m45
Gross margin compression
Gross margin has drifted from 5.0% (2022) to 3.6% (2026) — in a business already operating on wafer-thin spreads, this is a trend worth monitoring even if offset by opex discipline.
m38
Net debt position
Net cash of -$2.55B against $3.98B liquid cash (only 3.9% of market cap) — balance sheet is a constraint, not a cushion, though FCF easily services it.
m30
Insider selling with zero buys
10 sales totaling $23.9M over 12 months, 0 open-market buys; CFO Brian Tyler sold ~$17M across three months. Pattern is consistent with comp monetization but offers no insider conviction signal.
m35
Structural margin fragility
Operating on 1.5% operating margin means small disruptions (regulatory, contract loss, opioid-litigation-style shocks) can materially dent earnings — inherent to the pharma distribution oligopoly model.
This is a well-run distribution machine doing exactly what a mature earner should: growing the top line meaningfully, converting to cash reliably, and using that cash to shrink the share count aggressively. The forensic checks are clean across the board — no accruals games, no dilution, cash exceeds earnings. My concerns are structural rather than integrity-based: 1.5% operating margins leave no room for error, gross margin has drifted down 140 bps over four years, and the balance sheet is a working tool not a fortress. The insider tape is pure comp monetization, neutral signal. I'd call this a Strong business — solidly healthy, per-share value clearly being protected and grown, but not a moat-fortress given the razor-thin economics of the underlying trade.
Verify before trusting this (6)
  • Customer concentration disclosure — top pharma customers (CVS, Walmart, etc.) as percent of revenue
  • Remaining opioid litigation liabilities and settlement cash flow schedule
  • Composition of gross-margin decline — mix shift vs pricing pressure
  • Buyback authorization remaining and pace assumptions
  • Segment-level performance (US Pharma vs Prescription Technology Solutions vs International)
  • Working capital dynamics given the massive revenue scale and thin margins
Valuation / Mispricing
+16
Modestly Cheap
edge √Σ 77 · risk √Σ 61 · conf 6/10
price $875.51 vs deserved ~$940, roughly 7% discount - modestly cheap, not deeply mispriced attractive below $820.00

The e2e composite pins fair value at $938.92 (signal-adjusted $1,107.98) against a $875.51 price - a ~7% gap on the composite, ~27% on the signal-adjusted number. The methods disagree loudly: DCF at $981.94 is credible for a mid-single-digit grower with heavy buybacks; the anchored P/E at $1,358.47 looks like a runaway multiple on a 1.5%-margin distributor and should be discounted heavily; the EPV floor at $433 reminds us that without growth this is a much cheaper business. Splitting the difference around the DCF/composite ($940-$980) feels like honest deserved value. Earnings quality is high (score 3, no haircut needed) and the buyback is genuinely shrinking the float, both of which support - not inflate - the deserved number. What's priced in: continued low-single-digit distribution growth, steady specialty/oncology mix-shift, and disciplined capital return. What's NOT fully priced: a re-rating on software/services, or a tail hit from opioid liabilities or Amazon-style disintermediation. Net: a modest discount to a defensible fair value, not a screaming bargain. Margin of safety exists but is thin - call it 7-10%, not 25%.

Cheap signals 3
m55
Trades below DCF and composite fair value
$875.51 vs DCF $981.94 and composite $938.92 - a 7-11% discount on the most defensible methods, meaningful but not extreme.
m45
Aggressive buyback shrinks the deserved-price denominator
Company-quality lens flags aggressive share-count reduction with clean cash conversion; per-share value compounds even at flat EBIT, supporting the deserved price.
m30
High earnings quality - no haircut
Earnings-quality score 3 means the reported cash and EPS are trustworthy; deserved value does not need to be marked down for accruals or dilution games.
Rich / priced-in 3
m40
Anchored P/E fair value looks runaway
$1,358.47 implies a re-rating a 1.5% operating-margin distributor rarely earns; treating it as gospel would overstate the gap - discount this input heavily.
m35
EPV floor sits at $433
Without growth, steady-state earnings power is worth about half the current price - the discount to DCF only exists if the growth/mix-shift thesis holds.
m30
Structural tail risks not fully in the price
Opioid liability tail and Amazon/vertical-integration pressure on the 1.5% margin are real; a modest discount is arguably compensation, not a bargain.
Modestly cheap, not a fat pitch. At $875 against a defensible deserved value near $940, I get maybe 7-10% of margin of safety on a strong but structurally thin-margin business. The signal-adjusted $1,108 and the anchored-P/E $1,358 are too generous to lean on - the anchored multiple in particular looks like a method artifact for a distributor this thin. I would want it closer to $820 (roughly 12-15% below deserved) before I called it a real opportunity; at $875 it's a fine hold, a marginal add, and nothing to chase.
Verify before trusting this (5)
  • Specialty and oncology segment growth rates and margin contribution in latest 10-Q
  • Remaining opioid settlement cash outflows and any new claims
  • Buyback pace and remaining authorization
  • Prescription Technology Solutions (software) revenue growth and margin trajectory
  • Any guidance revisions to operating margin - the whole thesis rides on holding 1.5%+
General Sentiment
+5
Balanced
tail √Σ 61 · head √Σ 56 · conf 6/10

MCK sits in the quiet lane of the market. With a beta of 0.31, the mildly risk-on regime (score +52, VIX 14.3) delivers almost no lift here - high-beta story stocks are catching the bid, not healthcare distributors. The macro headwind from 4.63% 10y and a 26.2 market PE is similarly muted for a low-multiple, cash-generative name whose earnings stream is largely rate-insensitive. Net tape pressure on THIS ticker is close to zero.

Tailwinds 3
m42
Steady-compounder narrative intact
The market is telling a moderate-intensity, moderate-durability story around specialty/oncology mix-shift and recurring software - a boring but supportive frame that keeps sentiment from turning hostile even when the tape wobbles.
m38
Strong price momentum reinforcing the bid
A 14.3% CAGR with low volatility gives the name positive drift and trend-followers a reason to stay long; in a calm tape that momentum tends to persist rather than reverse.
m22
Risk-on tape - but muted through 0.31 beta
The market is +52 risk-on and 10 days into the regime, but a 0.31 beta means very little of that flows into MCK; it is a small positive, not a driver.
Headwinds 3
m45
Opioid/litigation tail overhang still in the story
The bear frame keeps opioid settlement risk and 'commoditized middleman' fears alive as the reason for the DCF discount - a persistent, low-grade press on sentiment that flares on any headline.
m30
Amazon/vertical-integration disruption meme
The distribution-disruption narrative is a background bear thesis for the whole cohort; low intensity today but caps how excited the market is willing to get about the name.
m15
Rates/market PE crosscurrent
Higher-for-longer rates and a 26.2 tape PE are a broad drag, but MCK's cash-generative, low-duration profile means the pressure barely lands here.
This is a low-beta defensive with a boring, durable story and no active narrative crisis - the risk-on tape gives it a whisper of lift, the opioid tail keeps a whisper of drag, and neither dominates. Slight positive drift from momentum and an intact compounder frame edges it just north of neutral, but nothing here is moving the stock on sentiment alone. Balanced, leaning marginally constructive.
Verify before trusting this (4)
  • Any fresh opioid settlement or state-AG headline that reignites the litigation overhang
  • Specialty/oncology mix commentary on next print - the pillar holding the compounder narrative
  • Sell-side target revisions or a sector rotation out of defensive healthcare into higher-beta names
  • Amazon Pharmacy or vertical-integrator news that could sharpen the disruption bear case
The market-wide tape + this name's exposure to it (beta / sector / narrative durability). Context on the non-fundamental pressure — not a call on the business or the price. processId: detail-general-sentiment
AI Impact
+40
Moderately favorable — physical core insulated, software wing is the real exposure
opp √Σ 101 · thr √Σ 0 · conf 7/10

McKesson's economics rest on physical throughput of licensed, high-value molecules and on being the entity regulators and manufacturers hold accountable for chain-of-custody — neither of which cheapens when intelligence does; AI arrives instead through three narrow channels: it compresses the cost of running a $403B logistics and receivables machine (accretive on razor-thin margins), it raises the market value of proprietary oncology real-world data and trial-matching capability (Ontada), and it threatens the per-transaction fee logic of the access/affordability software layer that the bull case depends on for mix-shift; the distribution moat is not code, so AI-native entrants cannot compress it, but AI-enabled direct-to-patient manufacturer channels can route around parts of it for specific branded drugs.

AI opportunities 8
m62
Underlying Need Persistence
Drugs must be physically sourced, stored, and delivered to ~pharmacies, clinics, and health systems regardless of intelligence costs.
m43
Solution Persistence
Wholesale three-tier distribution survives AI, but the software/access layer's delivery form is less certain.
m41
Responsibility Transfer
Customers and manufacturers pay McKesson partly to carry DEA, DSCSA, and product-integrity accountability.
m17
Scarcity Migration
As software becomes abundant, licensed physical networks and proprietary oncology data become the relatively scarce assets.
m19
Customer DIY Preference
Nobody wants to own drug logistics; some customers may want to own access workflows.
m19
Data Leverage
Oncology EHR and dispensing data are genuinely AI-relevant inputs, monetizable to manufacturers.
m32
Revenue Unit Durability
The monetized units — drug volume and fee-for-service on manufacturer contracts — survive AI; per-transaction software fees are shakier.
m29
Entrant Compression
AI lowers the cost of building software competitors, not licensed national drug distribution.
AI threats 0

None surfaced.

AI is a cost tailwind on a 1.5%-margin, $403B throughput machine and a threat only to the software wing the bulls are paying up for — so the trade is long the physical moat, skeptical of the mix-shift story. Position 60 with exposure 40: the licensed distribution core is close to AI-proof (entrant_compression 73, responsibility_transfer 79), and operating leverage on razor-thin margins means modest automation gains land directly in EPS. The soft spot is Prescription Technology Solutions, whose per-transaction access fees are the most AI-replicable revenue McKesson owns — if PTS growth converges toward distribution growth, the premium mix-shift narrative deflates even as earnings hold. Watch PTS segment revenue and operating profit decomposition, Ontada data-contract disclosure, and any manufacturer moving hub/access services in-house; those three read out before the market reprices.
Verify before trusting this (8)
  • Manufacturer direct-to-patient program expansion
  • Payer-side automated PA adoption
  • Contract renewals with top pharmacy customers
  • US script and specialty volume trends
  • GLP-1 and specialty unit growth
  • Site-of-care shifts away from distribution
  • PTS revenue vs technology-fee mix
  • Prior-auth transaction pricing trends
The structural effect of the AI wave on this specific business over the next ~5 years — demand, cost leverage, moat, barriers to entry, position in the AI stack. The reality beneath the AI story, not the story's market pressure (General Sentiment owns that) — and not a call on the business today or the price.
Growth Outlook
+44
Growing
edge √Σ 122 · risk √Σ 75 · conf 7/10

The world is pushing more drug value through fewer, larger pipes: biologics and specialty launches, GLP-1 mass adoption, aging demographics, and care migrating from hospital to community and home. Each of those adds units and complexity, and complexity is what a distributor is paid for. The offsetting force — payers, retailers and manufacturers trying to shorten the chain — is real but slow, and the capital intensity plus cold-chain/compliance scale of national distribution has repelled every entrant so far. Macro backdrop (4.63% 10y, headwind label) matters little: healthcare volume is non-discretionary and MCK's model is fee-based rather than price-levered, though higher rates do raise the bar on debt-funded roll-up M&A. Net: the environment supports steady volume growth with margin coming from services and specialty, not from distribution spread.

Growth drivers 5
m71
Specialty & oncology mix shift
Oncology and Multispecialty (US Oncology Network, community-practice roll-ups, vision/retina platforms) grows faster than commodity distribution and carries higher fee-for-service and services economics. This is the mechanism behind operating income growing far faster than revenue (recent earnings YoY +44.5% vs revenue +12.4%) and it is contractual/embedded, not a one-quarter effect.
m58
Volume-led distribution economics on branded/GLP-1 scripts
Distribution is paid on units and fee-for-service, not on drug price, so record GLP-1 and specialty script volume flows through with minimal incremental cost. Low gross margin percentage but high absolute contribution; three-player oligopoly (MCK/COR/CAH) means no need to buy volume with price.
m39
Prescription Technology Solutions
Access/affordability and adherence software attached to manufacturer hub programs is recurring, higher-margin, and grows with the same specialty launch cycle that drives distribution volume — a second, structurally different growth engine rather than a story about 'software'.
m53
EPS algorithm: leverage + share shrink
Consistent, sizeable repurchase converts ~high-single-digit operating income growth into low-to-mid-teens EPS growth. Mechanical, self-funded by strong FCF (FCF CAGR 21%), and independent of end-market surprises.
m46
Category in expansion phase
Sector demand cycle in expansion, industry revenue CAGR 8.3% and earnings CAGR 18.1%; aging demographics, biologic/biosimilar launch density and site-of-care shifts give the pipe more volume each year regardless of MCK's own execution.
Growth risks 5
m50
Revenue deceleration as volume comps lap
Revenue confidence data flags the quarterly trend as decelerating. Much of the 12%+ top line is pass-through mix (GLP-1, branded inflation) that laps hard; the reported growth rate almost certainly steps down even if profit dollars keep compounding.
m42
Customer concentration and contract renewals
A small number of very large retail/PBM-affiliated customers represent an outsized share of volume. Any renewal at worse economics, insourcing, or a retail-pharmacy bankruptcy removes revenue instantly and is outside management's control.
m22
Medical-Surgical Solutions softness
The primary-care/post-acute supply segment is exposed to illness-season variability and utilization softness, and has repeatedly been the drag inside otherwise strong prints. Small share of revenue but a visible earnings-mix headwind.
m20
Opioid settlement cash drain and residual legal tail
Multi-year fixed settlement payments consume free cash flow that would otherwise fund buybacks/M&A; incremental claimants remain possible. Known and scheduled, so it caps rather than reverses growth.
m21
Generic deflation and vertical integration/disintermediation
Persistent generic price erosion pressures the highest-margin part of the mix, and payer/provider vertical integration plus direct-to-patient manufacturer channels chip at the pipe's role at the margin. Slow-moving and historically absorbed, not yet visible in results.
vs expectations: ~6m above · 1y inline · 2-3y above
The forward growth verdict — is the business itself likely to grow (next 2 quarters / year 1 / years 2–3), judged against its category and against printed expectations. The full horizon ladder + creme renders on the Growth Outlook card above. Not a call on the price (Valuation owns that) or the tape (Sentiment owns that).
Please log in to view trade setups
The Augustus trade-setup read is a members feature.
Log in
Lenses kept deliberately separate — Company Quality (price-agnostic), Valuation (price-conditional), General Sentiment (non-fundamental macro/narrative pressure), AI Impact (structural ~5yr AI exposure), and Growth Outlook (the forward growth verdict). The scores are not blended. Filing-level items (convertibles, lock-ups, customer concentration) are v2 — see each lens's "verify."
Price Prediction
Higher +11.1% v0.6.0 View full prediction →

When we made this prediction on Aug 18, 2026, MCK was $859.92. We expect it to be $955.00 by Feb 2027, and we consider it great value under $820.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 18, 2026.

Price when predicted$859.92
Our estimate for Feb 2027$955.00+11.1%
Great value below$820.00
Price history shown (6 Months)

Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.

Community AI Feedback
No community reviews yet for MCK. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
v1.1.562 · 9b2927c4 · 2026-08-22 16:52:06